Loading...

Abzena

AIM:ABZA
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ABZA
AIM
£34M
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Abzena plc provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in North America, Europe, and internationally. The last earnings update was 130 days ago. More info.


Add to Portfolio Compare Print Invest
  • Abzena has significant price volatility in the past 3 months.
ABZA Share Price and Events
Price Volatility
ABZA
Industry
5yr Volatility vs Market

Value

 Is Abzena undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Abzena. This is due to cash flow or dividend data being unavailable. The share price is £0.1575.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Abzena's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Abzena's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:ABZA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-03-31) in GBP £-0.07
AIM:ABZA Share Price ** AIM (2018-10-11) in GBP £0.16
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 38.33x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 822 Publicly-Listed Companies 16.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Abzena.

AIM:ABZA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:ABZA Share Price ÷ EPS (both in GBP)

= 0.16 ÷ -0.07

-2.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abzena is loss making, we can't compare its value to the Europe Life Sciences industry average.
  • Abzena is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Abzena's expected growth come at a high price?
Raw Data
AIM:ABZA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.33x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
39.2%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 12 Publicly-Listed Life Sciences Companies 2.43x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 579 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

AIM:ABZA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -2.33x ÷ 39.2%

-0.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abzena is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Abzena's assets?
Raw Data
AIM:ABZA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-03-31) in GBP £0.20
AIM:ABZA Share Price * AIM (2018-10-11) in GBP £0.16
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 12 Publicly-Listed Life Sciences Companies 2.05x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,348 Publicly-Listed Companies 1.61x
AIM:ABZA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:ABZA Share Price ÷ Book Value per Share (both in GBP)

= 0.16 ÷ 0.20

0.77x

* Primary Listing of Abzena.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abzena is good value based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess Abzena's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Abzena has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Abzena expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Abzena expected to grow at an attractive rate?
  • Unable to compare Abzena's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Abzena's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as it is expected to be loss making during the next 1-3 years.
  • Abzena's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
AIM:ABZA Future Growth Rates Data Sources
Data Point Source Value (per year)
AIM:ABZA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 39.2%
AIM:ABZA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 21.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 14.4%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 3.1%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 11.2%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 4.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:ABZA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:ABZA Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-03-31 34 -6 1
2019-03-31 26 -11 1
AIM:ABZA Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-03-31 22 -15 -14
2017-12-31 21 -14
2017-09-30 19 -11 -13
2017-06-30 19 -9 -11
2017-03-31 19 -6 -9
2016-12-31 17 -10
2016-09-30 15 -10 -10
2016-06-30 13 -10 -10
2016-03-31 10 -11 -10
2015-12-31 8 -9 -8
2015-09-30 7 -6 -6
2015-06-30 6 -6 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Abzena is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Abzena's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:ABZA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Abzena Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:ABZA Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-03-31 -0.03 -0.03 -0.03 1.00
2019-03-31 -0.05 -0.05 -0.05 1.00
AIM:ABZA Past Financials Data
Date (Data in GBP Millions) EPS *
2018-03-31 -0.07
2017-12-31 -0.07
2017-09-30 -0.08
2017-06-30 -0.07
2017-03-31 -0.07
2016-12-31 -0.07
2016-09-30 -0.08
2016-06-30 -0.08
2016-03-31 -0.09
2015-12-31 -0.07
2015-09-30 -0.06
2015-06-30 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Abzena will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Abzena's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Abzena has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Abzena performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Abzena's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Abzena does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Abzena's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Abzena's 1-year growth to the Europe Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Abzena's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Abzena Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:ABZA Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-03-31 21.95 -14.16 18.60 6.16
2017-12-31 20.64 -13.64 17.85 5.92
2017-09-30 19.33 -13.12 17.72 5.05
2017-06-30 18.99 -11.12 16.16 4.45
2017-03-31 18.65 -9.12 13.99 4.47
2016-12-31 16.98 -9.66 12.89 4.51
2016-09-30 15.31 -10.20 11.79 4.56
2016-06-30 12.58 -9.95 10.42 4.39
2016-03-31 9.85 -9.70 9.05 4.22
2015-12-31 8.29 -7.65 7.72 3.67
2015-09-30 6.73 -5.60 6.39 3.13
2015-06-30 6.20 -5.16 6.01 3.06
2015-03-31 5.67 -4.72 5.63 2.99
2014-09-30 5.87 -3.06 4.79 2.73
2014-06-30 5.04 -2.95 4.31 2.40
2014-03-31 4.21 -2.84 3.83 2.08
2013-03-31 3.90 -0.16 2.57 1.73
2012-03-31 1.52 -1.07 1.95 0.63

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Abzena has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Abzena has efficiently used its assets last year compared to the Europe Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Abzena improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Abzena's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Abzena has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Abzena's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Abzena's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Abzena is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Abzena's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Abzena's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 29.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Abzena Company Filings, last reported 6 months ago.

AIM:ABZA Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-03-31 43.69 0.66 6.79
2017-12-31 43.69 0.66 6.79
2017-09-30 50.64 0.76 16.93
2017-06-30 50.64 0.76 16.93
2017-03-31 35.93 0.66 4.14
2016-12-31 35.93 0.66 4.14
2016-09-30 39.34 0.00 9.38
2016-06-30 39.34 0.00 9.38
2016-03-31 41.06 0.00 13.72
2015-12-31 41.06 0.00 13.72
2015-09-30 24.34 0.00 7.42
2015-06-30 24.34 0.00 7.42
2015-03-31 27.85 0.00 15.80
2014-09-30 29.91 0.00 18.67
2014-06-30 29.91 0.00 18.67
2014-03-31 13.53 0.00 2.76
2013-03-31 4.27 0.00 2.75
2012-03-31 4.20 0.00 2.41
  • Abzena's level of debt (1.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 1.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Abzena has less than a year of cash runway based on current financial obligations.
  • Abzena has less than a year of cash runway if financial obligations continue to grow at historical rates of 53.9% each year.
X
Financial health checks
We assess Abzena's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Abzena has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Abzena's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Abzena dividends.
If you bought £2,000 of Abzena shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Abzena's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Abzena's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:ABZA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.8%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 706 Stocks 5.4%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 1.9%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:ABZA Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2020-03-31 0.00 1.00
2019-03-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Abzena has not reported any payouts.
  • Unable to verify if Abzena's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Abzena's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Abzena has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Abzena's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Abzena's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Abzena afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Abzena has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Abzena's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
William John Burt, image provided by Google.
William John Burt
COMPENSATION £290,000
AGE 50
TENURE AS CEO 7.4 years
CEO Bio

Dr. William John Edward Burt, DPhil, has been the Chief Executive Officer of Abzena plc since May 26, 2011. Dr. Burt serves as an Executive Director of Abzena plc. He served as Chief Executive Officer of Antitope Limited and Thiakis, a company which he co-founded in 2004. He served as a Director of Antitope Ltd. Dr. Burt holds a D Phil (Molecular Biology) from University of Oxford following his First Degree in Natural Sciences at University of Cambridge.

CEO Compensation
  • William John's compensation has been consistent with company performance over the past year.
  • William John's remuneration is higher than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure of the Abzena management team in years:

7.4
Average Tenure
  • The average tenure for the Abzena management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

William John Burt

TITLE
CEO & Executive Director
COMPENSATION
£290K
AGE
50
TENURE
7.4 yrs

Sunil Shaunak

TITLE
Co-Founder & Chairman of the Scientific Advisory Board
TENURE
16.8 yrs

Antony Godwin

TITLE
Co-Founder
TENURE
17.8 yrs

Steve Brocchini

TITLE
Co-Founder
TENURE
17.8 yrs

Jim Mills

TITLE
Senior Vice President of Technical Operations

Campbell Bunce

TITLE
Senior Vice President of Scientific Operations
AGE
47
TENURE
2.9 yrs

Sven Lee

TITLE
Chief Business Officer
TENURE
2 yrs

Sanjeevani Ghone

TITLE
Vice President of Chemistry & Site Head
TENURE
0.8 yrs

Michelle Neaves

TITLE
Director of Financial Planning & Analysis
Board of Directors Tenure

Average tenure and age of the Abzena board of directors in years:

6.7
Average Tenure
59
Average Age
  • The tenure for the Abzena board of directors is about average.
Board of Directors

Ken Cunningham

TITLE
Chairman
AGE
65
TENURE
8.5 yrs

William John Burt

TITLE
CEO & Executive Director
COMPENSATION
£290K
AGE
50

Sunil Shaunak

TITLE
Co-Founder & Chairman of the Scientific Advisory Board

Tony Brampton

TITLE
Non-Executive Director
COMPENSATION
£35K
AGE
61
TENURE
11.3 yrs

Peter Grant

TITLE
Non-Executive Director
COMPENSATION
£35K
AGE
62
TENURE
4.3 yrs

Nigel Pitchford

TITLE
Non-Executive Director
COMPENSATION
£30K
AGE
48
TENURE
6.7 yrs

Lotta Ljungqvist

TITLE
Non-Executive Director
COMPENSATION
£18K
AGE
57
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Abzena insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Value (USD)
05. Oct 18 Buy Alexander Milne Individual 04. Oct 18 04. Oct 18 350,000 $72,285.15
17. Aug 18 Buy Oddo Bhf Asset Management SAS Company 16. Aug 18 16. Aug 18 2,510,732 $479,361.51
17. Aug 18 Sell Baillie Gifford & Co. Company 16. Aug 18 16. Aug 18 -2,737,935 $-515,538.48
X
Management checks
We assess Abzena's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Abzena has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Should You Worry About Abzena plc's (LON:ABZA) CEO Pay?

Understanding how CEOs are incentivised to run and grow their company is an important aspect of investing in a stock. … This is because, if incentives are aligned, more value is created for shareholders which directly impacts your returns as an investor. … CEOs leading companies of similar size and profitability

Simply Wall St -

Abzena plc (LON:ABZA): Risks You Need To Consider Before Buying

Generally, an investor should consider two types of risk that impact the market value of ABZA. … The second risk is market-wide, which arises from investing in the stock market. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one.

Simply Wall St -

Should Abzena plc's (LON:ABZA) Recent Earnings Decline Worry You?

After reading Abzena plc's (LON:ABZA) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … As a long-term investor I tend to focus on earnings trend, rather than a single number at one point in time. … ABZA is loss-making, with the most recent trailing twelve-month earnings of -UK£14.16m (from 31 March 2018), which compared to last year has become.

Simply Wall St -

Abzena plc (LON:ABZA): Are Analysts Optimistic?

Abzena plc's (LON:ABZA):. … Abzena plc engages in the provision of services and technologies for the development and commercialization of biopharmaceutical products in North America, Europe, the United Kingdom, and internationally. … Check out our latest analysis for Abzena

Simply Wall St -

Abzena plc (LON:ABZA): How Does It Impact Your Portfolio?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … Based on this beta value, ABZA appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … Therefore, investors can expect a high beta associated with the size of ABZA, but a lower beta given the nature of the industry it operates in.

Simply Wall St -

Should You Be Concerned About Abzena plc's (LON:ABZA) Investors?

General Public Ownership With 6.87% ownership, the general public are also an important ownership class in ABZA. … Private Company Ownership Another important group of owners for potential investors in ABZA are private companies that hold a stake of 0.022% in ABZA. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

Want To Invest In Abzena plc (LON:ABZA)? Here's How It Performed Lately

AIM:ABZA Income Statement Apr 19th 18 We can further assess Abzena's loss by looking at what the industry has been experiencing over the past few years. … Each year, for the past five years Abzena's top-line has risen by 36.03% on average, implying that the company is in a high-growth phase with expenses shooting ahead of revenues, leading to annual losses. … You should continue to research Abzena to get a more holistic view of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for ABZA’s future growth?

Simply Wall St -

Is Abzena plc (LON:ABZA) A Financially Sound Company?

With this increase in debt, ABZA's cash and short-term investments stands at UK£4.14M for investing into the business. … ABZA is not taking on too much debt commitment, which may be constraining for future growth. … Investors' risk associated with debt is virtually non-existent with ABZA, and the company has plenty of headroom and ability to raise debt should it need to in the future.Next Steps: ABZA’s cash flow coverage indicates it could improve its operating efficiency in order to meet demand for debt repayments should unforeseen events arise.

Simply Wall St -

Should You Buy Abzena plc (LON:ABZA) At £0.2525?

Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. … With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. … Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy ABZA.

Simply Wall St -

Analysts Expect Breakeven On The Horizon For Abzena plc (LON:ABZA)

I’ve put together a brief outline of industry analyst expectations for ABZA, its year of breakeven and its implied growth rate. … Check out our latest analysis for Abzena Expectation from analysts is ABZA is on the verge of breakeven. … What rate will ABZA have to grow year-on-year in order to breakeven on this date?

Simply Wall St -

Company Info

Map
Description

Abzena plc provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in North America, Europe, and internationally. Its technologies include antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation. It provides phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine storm prior to it being progressed into clinical development. It also offers antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and ADCs, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging conjugation technology. In addition, it provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; peptide synthesis, modifications, and analytics; mammalian manufacturing, which cover cell line, process, and analytical development, as well as cell banking; peptide synthesis, modifications, and analytics; bioconjugates and ADCs manufacturing; and custom, library, HPAPI, and payload synthesis. Further, it offers full-time equivalent and protein/BioNMR services; and analytical solutions. It serves biopharmaceutical companies and academic groups. Abzena plc was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom.

Details
Name: Abzena plc
ABZA
Exchange: AIM
Founded: 2014
£33,845,707
214,893,379
Website: http://www.abzena.com
Address: Abzena plc
Babraham Research Campus,
Babraham,
Cambridge,
Cambridgeshire, CB22 3AT,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM ABZA New Ordinary Shares London Stock Exchange AIM Market GB GBP 10. Jul 2014
Number of employees
Current staff
Staff numbers
236
Abzena employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/10/12 18:41
End of day share price update: 2018/10/11 00:00
Last estimates confirmation: 2018/09/14
Last earnings filing: 2018/06/04
Last earnings reported: 2018/03/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.